Activity Overview | This educational activity provides expert commentary focusing on contemporary approaches for the management of patients with myeloproliferative neoplasms. |
Topics |
- Defining MPNs and current classification
- Historical perspective and the discovery of Janus 2 (JAK2) mutations
- Development of JAK 1/2 inhibitors
- Impact of Janus kinase inhibition in myelofibrosis
- Future of therapy for MPNs
|
Discussants |
| |
|
Roundtable Discussion |
 |
Downloadable Slides |
|
|
Claire Harrison, DM, FRCP, FRCPath
St Guy’s and St Thomas’ Trust
London, United Kingdom
|
|
Srdan Verstovsek, MD, PhD
University of Texas, M. D. Anderson Cancer Center
Houston, Texas, United States
|
|
Ruben Mesa, MD
Mayo Clinic
Scottsdale, Arizona, United States
|
|
Guido Finazzi, MD
Ospedali Riuniti
Bergamo, Italy
|
|
Target Audience | This educational roundtable is intended for hematologists, oncologists, and other healthcare professionals interested in the management of patients with myeloproliferative neoplasms. This activity is intended for healthcare professionals based outside of the United States. |
 Learning Objectives | Upon completion of this educational activity, attendees should be able to:
- Describe the latest diagnostic guidelines and risk-stratification methods for the Philadelphia chromosome–negative myeloproliferative neoplasms (Ph-negative MPNs) and the implementation of these strategies into clinical practice
- Discuss the rationale and mechanisms of action for JAK inhibitors in the treatment of myelofibrosis, as well as important ongoing trials
- Evaluate recent clinical trial data on the efficacy and safety of novel therapies in the management of patients with Ph-negative MPNs, including JAK 1/2 inhibitors, and the practical implications of these data
- Identify current and emerging strategies for addressing symptoms of myelofibrosis and maintaining quality of life in patients with MPNs
|
Disclosures |
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
|
|
|
Activity Date | This roundtable discussion is available from 20 December 2011 to 20 December 2012. |
SPONSORSHIP | This activity is sponsored by prIME Oncology.
|
Support | Support for this activity is provided by Novartis Oncology.
|
|
